Stem cell bond issue has narrow lead in poll
By Associated Press,
Associated Press
| 10. 11. 2004
A controversial measure that would provide $3 billion in state bond money to pay for human embryonic stem cell research holds a narrow margin of support among voters, according to a new Field Poll.
Proposition 71, designed to get around the Bush administration's funding limits on such research, would authorize the state to sell bonds to provide annual payments of about $300 million to scientists and companies doing stem cell research.
The poll found that 46 percent of likely voters support the idea with 39 percent opposed and 15 percent undecided. The margin of error was 4.3 percentage points.
The numbers are a slight improvement from an August poll that found 45 percent supported the bond measure to 42 percent opposed.
Supporters of the proposition -- including a coalition of influential Democratic donors and several Silicon Valley tycoons -- have raised more than $12 million for the campaign and are running TV ads.
The Field Poll found that half of those surveyed said they had seen or heard something about the initiative -- an improvement since August of 10 percentage...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...